Navigation Links
Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
Date:11/1/2007

Results) database.

The analyses found a definitive overall increase in the survival of MM patients over the past decade. In particular, five-year survival increased from 28.8 to 34.7 percent, and 10-year survival increased from 11.1 to 17.4 percent. Importantly, survival increased most dramatically in the youngest age group - more than half (56.7 percent) of patients younger than 50 survived at least five years, and more than 40 percent (41.3 percent) survived at least 10 years. In real years, the average relative survival increased from four years after diagnosis in 1990-1992 to almost seven years after diagnosis in 2002-2004.

Patients age 50-59 also fared well, with approximately half (48.2 percent) surviving at least five years, and nearly a third (28.6 percent) surviving at least 10 years. However, only modest increases were seen in the age group 60-69, and virtually no improvement was seen in patients older than 70. Since about half of MM patients are diagnosed when they are 60 or older, the lack of improvement in the eldest groups is a critical finding of the research.

"The rise in survival among MM patients in this study may be attributed to improvements in stem cell protocols, supportive care, and therapies with better efficacy and lower toxicity," said Hermann Brenner, MD, of the Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, and lead author of the study. "However, the improvements among older patients in our analysis remained much more modest, suggesting a need to better understand the natural history and treatment options for multiple myeloma in this population."

Improved Survival in Multiple Myeloma and the Impact of Novel Therapies

A second study conducted by researchers at the Mayo Clinic evaluated outcomes for a large group of MM patients by comparing survival among two date-specific analyses - one from time of diagnosis and one from time of relapse - to better understand trends
'/>"/>

SOURCE American Society of Hematology
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
2. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
3. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
4. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
5. Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of Blindness in Premature Infants
6. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
7. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
8. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
9. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
10. Eurands Zentase Effective in Treating Exocrine Pancreatic Insufficiency, Studies Show
11. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... Monday, December 8, 2014 at 9:00 a.m. Eastern Time to ... th American Society of Hematology Annual Meeting and Exposition.  ... by dialing 877-443-5662 or access the webcast at www.isispharm.com ... time at the same address. ABOUT ISIS ...
(Date:11/18/2014)... 18, 2014  Renova Therapeutics, a biopharmaceutical company ... and other chronic diseases, announced that Daniel ... The company also completed its third round of ... board member brings decades of life science experience ... executive with more than 30 years of experience ...
(Date:11/17/2014)... STAAR Surgical Company (NASDAQ: STAA ... lenses and delivery systems for the eye, today announced ... Medical Technology & Diagnostics Forum in New ... Thursday, November 20 at 12:30 p.m. PT/3:30 p.m. ET. ... of the Company,s current business trends, financial results, and ...
Breaking Medicine Technology:Isis Pharmaceuticals to Host Webcast to Discuss ISIS-FXI Rx Data Presented at the ASH Annual Meeting 2Isis Pharmaceuticals to Host Webcast to Discuss ISIS-FXI Rx Data Presented at the ASH Annual Meeting 3Renova Therapeutics welcomes new board member, raises $7.52 million in Series C financing round 2Renova Therapeutics welcomes new board member, raises $7.52 million in Series C financing round 3STAAR Surgical To Present At The Canaccord Genuity 2014 Medical Technology & Diagnostics Forum 2
(Date:11/18/2014)... HealthDay Reporter MONDAY, Nov. 17, ... to extremely low levels with a combination drug appears ... patients with clogged arteries, a new study found. ... Vytorin, a drug that combines a cholesterol-lowering statin called ... investigator Dr. Christopher Cannon, a cardiologist at Brigham and ...
(Date:11/18/2014)... News) -- Women who started smoking at a young ... menstrual pain, a new study suggests. About 29 ... has been suspected as a risk factor for severe ... of the new study said. The researchers analyzed ... study of women,s health in Australia. About 14 percent ...
(Date:11/18/2014)... Hills, CA (PRWEB) November 18, 2014 ... and workflow solutions, announced today their Gold sponsorship of ... November 19th through Friday, November 21st at the Fargo, ... event offering targeted Microsoft Dynamics GP training sessions and ... the Microsoft campus is an excellent way for users ...
(Date:11/18/2014)... Recently, Wigsbuy has introduced its newest collection of ... greatly discounted prices now, up to 85% off. , Wigsbuy ... products, offering many real and synthetic hair products. In order ... uses high quality materials to make its hair wigs, which ... , “We are offering a full line of human ...
(Date:11/18/2014)... Thompson HealthDay Reporter , MONDAY, ... patients can safely take aspirin combined with a blood-thinning medication, ... a patient,s risk of early death, according to a new ... Heart Association in Chicago. The report was also published online ... data from more than a dozen clinical trials revealed no ...
Breaking Medicine News(10 mins):Health News:Cholesterol Drug Vytorin Linked to Reduced Heart Attack Risk 2Health News:Cholesterol Drug Vytorin Linked to Reduced Heart Attack Risk 3Health News:Study Ties Teen Smoking to Risk of Severe Menstrual Cramps 2Health News:Altec Joins the 2014 Great Plains User Conference (GPUC) as a Gold Sponsor, Demonstrating the Capabilities of Certified for Microsoft Dynamics Product doc-link 2Health News:Altec Joins the 2014 Great Plains User Conference (GPUC) as a Gold Sponsor, Demonstrating the Capabilities of Certified for Microsoft Dynamics Product doc-link 3Health News:It Is The Most Wonderful Time To Buy Full Lace Wigs At Wigsbuy.com 2Health News:Long-Term Use of Aspirin Plus Blood Thinner Is Safe: Study 2Health News:Long-Term Use of Aspirin Plus Blood Thinner Is Safe: Study 3
... Sudden cardiac,arrest is a leading cause of death ... condition, it is imperative that every school develop ... they need to respond,effectively to children and adults ... perform CPR and use an automated external defibrillator,(AED) ...
... Jones addressed the issue of health disparities during a,Ways ... part are,as follows., "Mr. Chairman, I am appreciative ... disparities as we continue to move forward with,health reform ... not just to my district, but to,districts across the ...
... on the Impact of ... Technology in Healthcare, PLANO, Texas, June 10 ... President, International Healthcare Guest: ... Humana, Perot Systems continues its series of ...
... drug approved for osteoporosis prevention and treatment has provided ... a breast cancer preventative for certain cancers. Women ... develop invasive, estrogen-receptor (ER) positive breast cancer compared with ... results of the randomized controlled trial will be published ...
... , , TUESDAY, June 10 (HealthDay News) -- Regardless of the ... women, and smoking increases any adult,s risk of death just ... according to new risk of death charts. , The charts, ... the Journal of the National Cancer Institute show ...
... Maine, June 10 Sen. Olympia Snowe,(R-ME), member ... Medicare,bill -- S.3101 -- that includes pharmacy-related provisions ... drug claims and delay the,implementation of Medicaid reimbursement ... RPh, owner of Waltz Pharmacy Inc. in,Camden, ME ...
Cached Medicine News:Health News:Statement of Robert O'Connor, M.D., M.P.H. Chair, American Heart Association, Emergency Cardiovascular Committee, on U.S. House of Representatives Passage of the Josh Miller HEARTS Act 2Health News:Tubbs Jones Addresses Health Disparities Issue During Hearing 2Health News:Healthcare Tech and the World: A New Perspective on Innovation in Healthcare 2Health News:Healthcare Tech and the World: A New Perspective on Innovation in Healthcare 3Health News:Anti-estrogen drug therapy reduces risk of invasive breast cancer in older women 2Health News:Anti-estrogen drug therapy reduces risk of invasive breast cancer in older women 3Health News:Researchers Update Risk-of-Death Charts 2Health News:Maine Community Pharmacy Owner Thanks Sen. Snowe for Supporting Inclusion of Common-Sense Reimbursement Provisions in Medicare Bill 2
Shafts angled 8 mm from tip to bend with smooth jaws. Flat, cross action handle with holes and dull finish....
... designed with thinner, long jaws to ... through a tunnel or clear corneal ... lens securely, but will not damage ... enough to allow the lens to ...
Titanium. Designed to easily fold the hydroview lens. Will also fold many styles of soft intraocular lenses. Unique cross-action design facilitates folding of the lens....
Angled 45 degree shafts. 7 mm from tip to bend with grooved 2 mm platform for grasping lens haptic. Serrated McPherson style handle with dull finish....
Medicine Products: